Transthyretin Amyloid Cardiomyopathy
Cardiovascular·MeSH: Amyloidosis
8 drugs in development·6 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| attruby | BridgeBio Pharma, Inc. (BBIO) |
Phase 3(5)
Phase 2(1)
| Drug | Company |
|---|---|
| alxn2220 | ASTRAZENECA PLC (AZN) |
Phase 1(1)
| Drug | Company |
|---|---|
| coramitug | Novo Nordisk A/S (NVO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Transthyretin Amyloid Cardiomyopathy?
BioSniper tracks 8 drugs in development for Transthyretin Amyloid Cardiomyopathy across 6 companies.
How many clinical trials target Transthyretin Amyloid Cardiomyopathy?
There are 5 clinical trials targeting Transthyretin Amyloid Cardiomyopathy tracked by BioSniper.
Deep-dive into Transthyretin Amyloid Cardiomyopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis